Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JBKZ | ISIN: GB00BF5G6K95 | Ticker-Symbol: RQE1
Frankfurt
05.02.24
09:15 Uhr
0,034 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
RENEURON GROUP PLC Chart 1 Jahr
5-Tage-Chart
RENEURON GROUP PLC 5-Tage-Chart

Aktuelle News zur RENEURON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.TRADING UPDATES: ReNeuron appoints administrators as rescue talks fail1
20.03.FTSE Russell - ReNeuron Group: Constituent Deletion - Changes in FTSE UK Index Series-
20.03.ReNeuron Group plc - Appointment of Administrators-
20.03.ReNeuron Group plc - Intention to Appoint Administrators-
05.02.TRADING UPDATES: ReNeuron warns; Gama Aviation pledges cash return3
05.02.Reneuron issues administration warning as biotech firm puts jobs at risk1
05.02.XFRA RQE1: AUSSETZUNG/SUSPENSION232DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILRENEURON GRP PLC...
► Artikel lesen
05.02.AIM - Suspension - ReNeuron Group plc-
05.02.ReNeuron Group plc - Corporate update and suspension of trading on AIM-
27.11.23Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX278Edison Investment Research Limited Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX 27-Nov-2023 / 08:53 GMT/BST The issuer is solely responsible...
► Artikel lesen
27.11.23ReNeuron Group - H124 results reaffirm focus on CustomEx353ReNeuron has announced its H124 results (to end-September 2023), reaffirming its commitment to advance CustomEx , its proprietary stem cell-derived exosome delivery platform. The key operational update...
► Artikel lesen
08.11.23ReNeuron interim loss narrows on lower costs; eyes partnerships2
08.11.23ReNeuron Group plc - Interim Results for the six months ended 30 Sept1
08.11.23ReNeuron Group plc - ReNeuron presents in vivo data at Cell 2023-
18.09.23EQS-News: ReNeuron Group (RENE): A step forward on the Exosome delivery platform366EQS-News: / Key word(s): Research Update/Research Update ReNeuron Group (RENE): A step forward on the Exosome delivery platform 18.09.2023 / 08:15 CET/CEST The...
► Artikel lesen
15.09.23ReNeuron Group - A step forward on the Exosome delivery platform330ReNeuron Group has generated in vivo data for CustomEX, marking a key step towards validating its proprietary stem cell-derived exosome platform. While the precise nature of the data is yet to be disclosed...
► Artikel lesen
30.05.23ReNeuron Group - Full steam ahead with CustomEx451ReNeuron's FY23 results provide a recap of financial and operational highlights from the period. Following the restructuring announcement in January 2023, the company's focus rests on its proprietary...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1